{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:11:34Z","timestamp":1777493494954,"version":"3.51.4"},"reference-count":57,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the impact of long-term pharmacotherapy with guanfacine immediate- or extended-release (GXR), administered alone or as an adjunctive to a stimulant, on weight and height in children and adolescents with attention-deficit\/hyperactivity disorder (ADHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data were extracted from U.S. Department of Defense medical records for patients 4\u201317 years of age at index date (initiation of any study medication following a year without ADHD medications, or diagnosis if unmedicated) with weight\/height measurements for the analysis period (January 2009\u2013June 2013) and the previous year (baseline). Longitudinal weight and height\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -scores were analyzed using multivariable regression in three cohorts: guanfacine (initial period of guanfacine exposure), first-line stimulant monotherapy (initial period of exposure), and unmedicated. Guanfacine cohort subgroups were based on previous\/concurrent stimulant exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The weight analyses included 47,910 patients (66.8% male) and the height analyses 41,248 (67.2% male). Mean initial exposure in the weight analyses was 237 days (standard deviation [SD]\u2009=\u2009258, median\u2009=\u2009142) for guanfacine and 257 days (SD\u2009=\u2009284, median\u2009=\u2009151) for first-line stimulant monotherapy, and was similar in the height analyses. Modeling indicated that guanfacine monotherapy was not associated with clinically meaningful deviations from normal\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score trajectories for weight (first-line,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009943; nonfirst-line,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009796) or height (first-line,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009741; nonfirst-line,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009644). In patients receiving guanfacine adjunctive to a stimulant, modeled weight (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091657) and height (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091343)\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -scores followed declining trajectories. In this subgroup, mean standardized weight\/height had decreased during previous stimulant monotherapy. For first-line stimulant monotherapy, modeled weight (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200932,999) and height (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200928,470)\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -scores followed declining trajectories during year 1. In the unmedicated cohort, modeled weight (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200911,515) and height (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200910,050)\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -scores were stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Guanfacine monotherapy (first-line or nonfirst-line) was not associated with marked deviations from normal growth in this modeling study of children and adolescents with ADHD. In contrast, growth trajectories followed an initially declining course with stimulants, whether given alone or with adjunctive guanfacine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2018.0132","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T14:01:43Z","timestamp":1554300103000},"page":"285-304","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Weight and Height in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy"],"prefix":"10.1177","volume":"29","author":[{"given":"Gary","family":"Schneider","sequence":"first","affiliation":[{"name":"Evidera, Waltham, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Naval Medical Center Portsmouth, Portsmouth, Virginia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per A.","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine and Department of Child and Adolescent Psychiatry, Link\u00f6ping University, Link\u00f6ping, Sweden."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Murphy","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Coghill","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia."},{"name":"Murdoch Children's Research Institute, Melbourne, Australia."},{"name":"Division of Neuroscience, University of Dundee, Dundee, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Spalding","sequence":"additional","affiliation":[{"name":"Shire, now part of Takeda, Lexington, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"e_1_3_4_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0514-8"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900017107"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.04.025"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199509000-00010"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010123431501"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0443-y"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073811422752"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-13-00430"},{"key":"e_1_3_4_13_1","unstructured":"European Medicines Agency: Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. 2009. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Methylphenidate_31\/WC500011184.pdf (Accessed April23 2018)."},{"key":"e_1_3_4_14_1","unstructured":"European Medicines Agency: Assessment report for Dexamed 5mg tablets and associated names. 2014. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Dexamed_29\/WC500172118.pdf (Accessed April23 2018)."},{"key":"e_1_3_4_15_1","unstructured":"European Medicines Agency: Summary of the risk management plan (RMP) for Intuniv (guanfacine). 2015. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003759\/WC500190181.pdf (Accessed April23 2018)."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.ObO13e31817eOea7"},{"key":"e_1_3_4_17_1","unstructured":"Flegal KM Cole TJ: Construction of LMS Parameters for the Centers for Disease Control and Prevention 2000 Growth Charts. National Health Statistics Reports; No. 63. Hyattsville MD National Center for Health Statistics 2013. Available from: www.cdc.gov\/nchs\/data\/nhsr\/nhsr063.pdf (Accessed April23 2018)."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2009.28335"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.03.004"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-918"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.991716"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.09.014"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-13-00334"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1995.5.215"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781848607958.n11"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199501000-00013"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-018-1113-4"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203229"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0025"},{"key":"e_1_3_4_30_1","first-page":"1","article-title":"2000 CDC Growth Charts for the United States: Methods and development","volume":"11","author":"Kuczmarski RJ","year":"2002","unstructured":"Kuczmarski RJ, , Ogden CL, , Guo SS, , Grummer-Strawn LM, , Flegal KM, , Mei Z, , Wei R, , Curtin LR, , Roche AF, , Johnson CL: 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat, 11:1\u2013190, 2002.","journal-title":"Vital Health Stat"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-13-211"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133428"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.05.015"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.974549"},{"key":"e_1_3_4_35_1","unstructured":"National Center for Health Statistics: Health United States 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville MD USA 2016. (Accessed April23 2018)."},{"key":"e_1_3_4_36_1","unstructured":"National Center for Health Statistics and the Centers for Medicare and Medicaid Services: ICD-9-CM diagnosis and procedure codes: Version 31 abbreviated and full code titles\u2013effective October 1 2013. 2013. Available from: www.cms.gov\/Medicare\/Coding\/ICD9ProviderDiagnosticCodes\/Downloads\/cmsv31-master-descriptions.zip (Accessed April23 2018)."},{"key":"e_1_3_4_37_1","unstructured":"National Institute for Health and Care Excellence: Attention deficit hyperactivity disorder: Diagnosis and management (NG87). National Institute for Health and Care Excellence 2018. Available from: www.nice.org.uk\/guidance\/ng87\/resources\/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933 (Accessed April23 2018)."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12492"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12745"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318054e724"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.056952"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0080"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnr.2005.09.010"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1067"},{"key":"e_1_3_4_46_1","unstructured":"Shionogi & Co. Ltd: Intuniv prescribing information. October 2017. Available from: www.shionogi.co.jp\/med\/download.php?h=0afb67b154bdb523e43f5095ce7ed1f8 (Accessed March20 2019)."},{"key":"e_1_3_4_47_1","unstructured":"Shire Pharma Canada ULC: Product monpgraph: Intuniv XR\u00ae. Shire Pharma Canada ULC January 2019. Available from: www.shirecanada.com\/-\/media\/shire\/shireglobal\/shirecanada\/pdffiles\/product%20information\/intuniv-xr-pm-en.pdf (Accessed March20 2019)."},{"key":"e_1_3_4_48_1","unstructured":"Shire Pharmaceuticals Ltd.: Intuniv: Summary of product characteristics. November 2017. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003759\/WC500195130.pdf (Accessed March20 2019)."},{"key":"e_1_3_4_49_1","unstructured":"Shire US Inc.: Prescribing information: Intuniv. March 2018. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022037s016lbl.pdf (Accessed March20 2019)."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3459"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.S3.501"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199611000-00014"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12684"},{"key":"e_1_3_4_54_1","unstructured":"United States Census Bureau: Annual estimates of the resident population by single year of age and sex for the United States: April 1 2010 to July 1 2015: 2014 Population estimates. 2016. Available from: http:\/\/factfinder.census.gov\/bkmk\/table\/1.0\/en\/PEP\/2015\/PEPSYASEXN (Accessed October11 2016)."},{"key":"e_1_3_4_55_1","unstructured":"US Department of Defense:. 2014 demographics. Profile of the military community. Office of the Deputy Assistant Secretary of Defense 2014. Available from: http:\/\/download.militaryonesource.mil\/12038\/MOS\/Reports\/2014-Demographics-Report.pdf (Accessed April23 2018)."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000197868"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1955"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.08.016"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2018.0132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2018.0132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2018.0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:25Z","timestamp":1777388125000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2018.0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1089\/cap.2018.0132"],"URL":"https:\/\/doi.org\/10.1089\/cap.2018.0132","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}